AGENUS INC (AGEN) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Win; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth Win; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth Win; EPS growth Lose.
- 2025-Q3: Total return Lose; Revenue growth Lose; EPS growth Lose.
38/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 4 wins, 8 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/3 |
LoseAGEN / S&P -8.38% / 15.20% |
WinAGEN / S&P 30.47% / 15.00% |
LoseAGEN / S&P -136.60% / 50.40% |
| 2026-Q12/3 |
WinAGEN / S&P 6.37% / -4.33% |
WinAGEN / S&P 24.46% / 11.30% |
LoseAGEN / S&P -118.55% / 27.70% |
| 2025-Q41/3 |
LoseAGEN / S&P -18.44% / 2.65% |
WinAGEN / S&P 10.37% / 9.00% |
LoseAGEN / S&P -95.65% / 13.40% |
| 2025-Q30/3 |
LoseAGEN / S&P -15.75% / 8.12% |
LoseAGEN / S&P -33.41% / 4.61% |
LoseAGEN / S&P -81.48% / 13.45% |
| 2025-Q21/3 |
WinAGEN / S&P 202.65% / 10.94% |
LoseAGEN / S&P -36.29% / 4.83% |
LoseAGEN / S&P -36.88% / 10.63% |
| 2025-Q10/3 |
LoseAGEN / S&P -44.89% / -4.27% |
LoseAGEN / S&P -38.34% / 4.98% |
LoseAGEN / S&P -31.88% / 10.57% |
| 2024-Q40/3 |
LoseAGEN / S&P -50.00% / 2.41% |
LoseAGEN / S&P -33.81% / 5.25% |
LoseAGEN / S&P -23.61% / 6.15% |
| 2024-Q31/3 |
LoseAGEN / S&P -67.28% / 5.89% |
WinAGEN / S&P 59.00% / 5.89% |
LoseAGEN / S&P -58.84% / 6.11% |
| 2024-Q22/3 |
WinAGEN / S&P 44.40% / 4.28% |
WinAGEN / S&P 60.66% / 5.38% |
LoseAGEN / S&P -52.53% / 5.12% |
| 2024-Q11/3 |
LoseAGEN / S&P -30.12% / 10.56% |
WinAGEN / S&P 69.94% / 5.71% |
LoseAGEN / S&P -36.37% / 5.59% |
| 2023-Q41/3 |
LoseAGEN / S&P -26.55% / 11.69% |
WinAGEN / S&P 59.46% / 6.81% |
LoseAGEN / S&P -11.50% / 7.78% |
| 2023-Q32/3 |
LoseAGEN / S&P -29.37% / -3.27% |
WinAGEN / S&P 12.23% / 7.52% |
WinAGEN / S&P 3070.24% / -5.03% |
| 2023-Q20/3 |
LoseAGEN / S&P 7.26% / 8.74% |
LoseAGEN / S&P -68.96% / 9.50% |
LoseAGEN / S&P -33714.29% / -8.57% |
| 2023-Q11/3 |
LoseAGEN / S&P -36.67% / 7.50% |
LoseAGEN / S&P -69.35% / 10.77% |
WinAGEN / S&P 15107.69% / -15.69% |
| 2022-Q41/3 |
WinAGEN / S&P 17.07% / 7.56% |
LoseAGEN / S&P -66.85% / 11.88% |
LoseAGEN / S&P AGEN unavailable / -17.99% |
| 2022-Q31/3 |
WinAGEN / S&P 5.67% / -4.88% |
LoseAGEN / S&P -70.68% / 13.47% |
LoseAGEN / S&P AGEN unavailable / -1.41% |
| 2022-Q21/3 |
LoseAGEN / S&P -21.14% / -16.10% |
WinAGEN / S&P 366.97% / 13.71% |
LoseAGEN / S&P AGEN unavailable / 11.04% |
| 2022-Q11/3 |
LoseAGEN / S&P -23.60% / -4.60% |
WinAGEN / S&P 265.60% / 15.97% |
LoseAGEN / S&P AGEN unavailable / 42.23% |
| 2021-Q41/3 |
LoseAGEN / S&P -38.67% / 11.03% |
WinAGEN / S&P 235.34% / 15.00% |
LoseAGEN / S&P AGEN unavailable / 96.40% |
| 2021-Q31/3 |
LoseAGEN / S&P -4.37% / 0.58% |
WinAGEN / S&P 235.50% / 10.77% |
LoseAGEN / S&P AGEN unavailable / 69.42% |
| 2021-Q21/3 |
WinAGEN / S&P 101.84% / 8.55% |
LoseAGEN / S&P -28.98% / 6.58% |
LoseAGEN / S&P AGEN unavailable / 51.81% |
| 2021-Q11/3 |
LoseAGEN / S&P -14.47% / 6.17% |
WinAGEN / S&P -0.61% / -1.06% |
LoseAGEN / S&P AGEN unavailable / 7.39% |
| 2020-Q40/3 |
LoseAGEN / S&P -20.50% / 12.15% |
LoseAGEN / S&P -41.24% / -3.72% |
LoseAGEN / S&P AGEN unavailable / -33.42% |
| 2020-Q30/3 |
LoseAGEN / S&P 1.78% / 8.93% |
LoseAGEN / S&P -25.08% / -2.04% |
LoseAGEN / S&P AGEN unavailable / -27.10% |
| 2020-Q21/3 |
WinAGEN / S&P 60.41% / 20.54% |
LoseAGEN / S&P -15.97% / -0.46% |
LoseAGEN / S&P AGEN unavailable / -27.11% |
| 2020-Q10/3 |
LoseAGEN / S&P -39.80% / -19.60% |
LoseAGEN / S&P -25.87% / 3.47% |
LoseAGEN / S&P AGEN unavailable / -14.75% |
| 2019-Q42/3 |
WinAGEN / S&P 57.75% / 9.07% |
WinAGEN / S&P 307.91% / 5.36% |
LoseAGEN / S&P AGEN unavailable / 2.99% |
| 2019-Q31/3 |
LoseAGEN / S&P -14.00% / 1.70% |
WinAGEN / S&P 215.34% / 5.02% |
LoseAGEN / S&P AGEN unavailable / 0.21% |
| 2019-Q21/3 |
LoseAGEN / S&P 1.01% / 4.30% |
WinAGEN / S&P 292.75% / 6.64% |
LoseAGEN / S&P AGEN unavailable / 8.65% |
| 2019-Q12/3 |
WinAGEN / S&P 24.79% / 13.65% |
WinAGEN / S&P 555.23% / 8.12% |
LoseAGEN / S&P AGEN unavailable / 14.29% |
| 2018-Q41/3 |
WinAGEN / S&P 11.21% / -13.52% |
LoseAGEN / S&P -14.21% / 9.05% |
LoseAGEN / S&P AGEN unavailable / 18.23% |
| 2018-Q30/3 |
LoseAGEN / S&P -5.73% / 7.71% |
LoseAGEN / S&P -3.52% / 10.21% |
LoseAGEN / S&P AGEN unavailable / 19.06% |
| 2018-Q20/3 |
LoseAGEN / S&P -51.80% / 3.43% |
LoseAGEN / S&P -28.99% / 9.03% |
LoseAGEN / S&P AGEN unavailable / 14.46% |
| 2018-Q11/3 |
WinAGEN / S&P 44.48% / -0.76% |
LoseAGEN / S&P -59.70% / 7.68% |
LoseAGEN / S&P AGEN unavailable / 12.46% |
| 2017-Q41/3 |
LoseAGEN / S&P -26.08% / 6.64% |
WinAGEN / S&P 89.95% / 7.03% |
LoseAGEN / S&P AGEN unavailable / 13.82% |
| 2017-Q32/3 |
WinAGEN / S&P 12.79% / 4.48% |
WinAGEN / S&P 62.76% / 5.68% |
LoseAGEN / S&P AGEN unavailable / 17.57% |
| 2017-Q22/3 |
WinAGEN / S&P 3.71% / 3.09% |
WinAGEN / S&P 52.32% / 4.83% |
LoseAGEN / S&P AGEN unavailable / 17.74% |
| 2017-Q11/3 |
LoseAGEN / S&P -8.50% / 6.07% |
WinAGEN / S&P 62.44% / 3.67% |
LoseAGEN / S&P AGEN unavailable / 13.32% |
| 2016-Q40/3 |
LoseAGEN / S&P -42.62% / 3.82% |
LoseAGEN / S&P -9.04% / 2.09% |
LoseAGEN / S&P AGEN unavailable / 7.05% |
| 2016-Q32/3 |
WinAGEN / S&P 77.28% / 3.85% |
WinAGEN / S&P 31.06% / 0.20% |
LoseAGEN / S&P AGEN unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | AGEN total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 86.84% | 20.78% |
| Annualized return | 86.84% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | AGEN total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -93.57% | 83.14% |
| Annualized return | -42.24% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | AGEN total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -93.57% | 319.30% |
| Annualized return | -24.00% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |